title: Development of novel PET probes, [18F]BCPP-EF, [18F]BCPP-BF, and [11C]BCPP-EM for mitochondrial complex 1 imaging in the living brain.
abstract: We developed three novel positron-emission tomography (PET) probes, 2-tert-butyl-4-chloro-5-{6-[2-(2[(18)F]fluoroethoxy)-ethoxy]-pyridin-3-ylmethoxy}-2H-pyridazin-3-one ([(18)F]BCPP-EF), 2-tert-butyl-4-chloro-5-[6-(4-[(18) F]fluorobutoxy)-pyridin-3-ylmethoxy]-2H-pyridazin-3-one ([(18)F]BCPP-BF), and 2-tert-butyl-4-chloro-5-{6-[2-(2-[(11)C]methoxy-ethoxy)-ethoxy]-pyridin-3-ylmethoxy}-2H-pyridazin-3-one ([(11)C]BCPP-EM), for quantitative imaging of mitochondrial complex 1 (MC-1) activity in vivo. These three PET probes were successfully labeled by nucleophilic [(18)F]fluorination or by [(11)C]methylation of their corresponding precursor with sufficient radioactivity yield, good radiochemical purity, and sufficiently high specific radioactivity for PET measurement. The specificity of these probes for binding to MC-1 was assessed with rotenone, a specific MC-1 inhibitor, by a rat brain slice imaging method in vitro. Rat whole-body imaging by small-animal PET demonstrated that all probes showed high uptake levels in the brain as well as in the heart sufficient to image them clearly. The rank order of uptake levels in the brain and the heart just after injection was as follows: high in [(18)F]BCPP-BF, intermediate in [(11)C]BCPP-EM, and low in [(18) F]BCPP-EF. The kinetics of [(18)F]BCPP-EF and [(11)C]BCPP-EM provided a reversible binding pattern, whereas [(18)F]BCPP-BF showed nonreversible accumulation-type kinetics in the brain and heart. Metabolite analyses indicated that these three compounds were rapidly metabolized in the plasma but relatively stable in the rat brain up to 60 min post-injection. The present study demonstrated that [(18)F]BCPP-EF could be a useful PET probe for quantitative imaging of MC-1 activity in the living brain by PET.
authors.affiliation: Central Research Laboratory, Hamamatsu Photonics K. K., Hamamatsu, Shizuoka, 434-8601, Japan.
authors.forename: Norihiro
authors.initials: N
authors.lastname: Harada
authors.forename: Shingo
authors.initials: S
authors.lastname: Nishiyama
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Kanazawa
authors.forename: Hideo
authors.initials: H
authors.lastname: Tsukada
mesh_terms: D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging*; D002250:Carbon Radioisotopes / Q000737:chemistry / Q000493:pharmacokinetics; D042967:Electron Transport Complex I / Q000378:metabolism; D008297:Male; D049268:Positron-Emission Tomography; D011485:Protein Binding; D011724:Pyridazines / Q000138:chemical synthesis* / Q000493:pharmacokinetics*; D011725:Pyridines / Q000138:chemical synthesis* / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: C000589725:2-tert-butyl-4-chloro-5-(6-(2-(2-(methoxyethoxy)ethoxy)pyridin-3-ylmethoxy)-2H-pyridazin-3-one; C588084:2-tert-butyl-4-chloro-5-(6-(2-(2-fluoroethoxy)ethoxy)pyridin-3-ylmethoxy)-2H-pyridazin-3-one; C588085:2-tert-butyl-4-chloro-5-(6-(4-fluorobutoxy)pyridin-3-ylmethoxy)-2H-pyridazin-3-one; D002250:Carbon Radioisotopes; D011724:Pyridazines; D011725:Pyridines; D019275:Radiopharmaceuticals; D042967:Electron Transport Complex I
keywords: PET; [11C]BCPP-EM; [18F]BCPP-BF; [18F]BCPP-EF; brain; mitochondrial complex 1